EPS for Zynerba Pharmaceuticals, Inc. (ZYNE) Expected At $-0.64 as of May, 8

April 17, 2018 - By Mary Markley

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Corporate Logo

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)’s earnings report is awaited by WallStreet on May, 8, Zacks reports. This year’s earnings per share analyst estimate is awaited to be $-0.64. That is 6.67 % down compareed to $-0.6 earnings per share for last year. Analysts at Wall Street see Zynerba Pharmaceuticals, Inc.’s 6.67 % negative EPS growth compared to $-0.60 earnings per share for last quarter. On during the last trading session the stock decreased $0.15 or 1.47%, reaching $10.02.Currently Zynerba Pharmaceuticals, Inc. is downtrending after 59.88% change in last April 17, 2017. ZYNE has also 159,528 shares volume. The stock underperformed the S&P500 by 71.43%.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.The firm is valued at $135.89 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain.Currently it has negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.